Approved: Sorafenib and Lenvatinib for the Treatment of Progressive, RAI-Refractory DTC

 

Related Videos (117)

In this video, Marcia S. Brose, MD, provides an overview of sorafenib and lenvatinib, the currently approved multikinase inhibitors for thyroid cancer. During her presentation, Dr. Brose analyzes the DECISION trial, which explored the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioiodine (RAI) refractory thyroid cancer, and the SELECT trial, which evaluated lenvatinib in RAI refractory differentiated thyroid cancer. Her talk involves the design, endpoints, treatment-emergent adverse events, subgroup analyses and outcomes for both studies.

View the 2015 presentation here

 

Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®